Sentences with phrase «urothelial cancer»

I am a urologic oncologist and surgeon - scientist focused on using modern scientific tools to improve the management of urothelial cancers of the bladder and upper tract.

A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with Metastatic Urothelial Cancer

Cytology detected upper tract urothelial cancers in only 10 percent of those patients.

Researchers at The Johns Hopkins Kimmel Cancer Center have developed a test for urine, gathered during a routine procedure, to detect DNA mutations identified with urothelial cancers.

The patients all had advanced urothelial cancer that had already been treated with platinum - based chemotherapy.

Roche said a phase III IMvigor211 study that evaluated the drug in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with chemotherapy «did not meet its primary endpoint of overall survival compared to chemotherapy.»

The designation is specifically for patients with locally advanced or metastatic urothelial cancer who have previously been treated with immune checkpoint inhibitors.

Participants have been asked to take part in this research study because they have metastatic or surgically unresectable urothelial cancer with FGF / FGFR alterations.

We are also examining how gene expression changes caused by chromatin modifier mutations interact with other commonly mutated pathways in urothelial cancers such as RTK - RAS - RAF and PI3K - AKT - MTOR to influence therapeutic response and resistance.

We are investigating how chromatin modifier mutations act to promote urothelial cancer development and potentially render these cancers susceptible to novel drug combinations.

Our lab is focused on understanding the effects of chromatin modifier mutations on the initiation and progression of urothelial cancers of the bladder and upper tract.

AA is implicated in multiple cancer types, sometimes with very high mutational burdens, especially in upper tract urothelial cancers (UTUCs).

«The FDA Breakthrough Therapy designation underscores the potential of enfortumab vedotin as a meaningful treatment for patients with locally advanced or metastatic urothelial cancer,» said Robert Lechleider, MD, the vice president of clinical development at Seattle Genetics, according to a press release.

Saying current noninvasive approaches for detection of urothelial cancer are suboptimal, researchers wanted to develop a test for bladder and UTUC cancer that would allow it to be found sooner and cheaper than current methods using cytology, which is not particularly sensitive and does not do well in detecting low - grade bladder cancer or UTUC.

Of 56 patients with upper tract urothelial cancer, 75 percent tested positive using UroSEEK, including 79 percent of those with noninvasive tumors.

UroSEEK uses urine samples to seek out mutations in 11 genes or the presence of abnormal numbers of chromosomes that would indicate the presence of DNA associated with bladder cancer or upper tract urothelial cancer (UTUC).

April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

Research Interests: bladder cancer; upper tract urothelial cancer; epigenetics; chromatin; histones; methylation; drug response; drug resistance; urology

Chromatin modifiers control how DNA is organized inside a cell's nucleus, and they are mutated in the majority of urothelial cancers.